The low-code software specialist finishes 2017 with a bang.
These three growth stocks are trading on the cheap, which is why this Fool would be a happy buyer today.
The biopharmaceutical's stock took a tumble after a Wall Street Journal article asserted that the company has been breaking the law.
Looking to cash in on the genomic revolution? Take a closer look at these three stocks.
Want to get in early on a few stocks that hold tremendous long-term potential? Here are three to consider.
Our healthcare experts see Celgene, Pfizer, and Alkermes as investments worth considering today. Here's why you should, too.
Shares tumble after the company receives an analyst downgrade. Here's what investors need to know.
Shares rally after management gives a presentation at an investor conference. Here's what investors need to know.
Shares plunged after the company announced that it is delaying its earnings release date in order to conduct an accounting review.
The leading provider of services and data for the life sciences industry posted double-digit gains in revenue and profits.
Higher revenue and falling costs combined to swing Mazor's bottom-line into the black.
The commercial-stage biopharma caps off 2017 on a high note and prescribes itself a healthy future.
Want to cash in on the life sciences boom? Here are three stocks to check out.
Looking for a few companies that you can safely own for the ultra-long term? Start with these three.
Favorable regulatory news causes traders to cheer.
Expectation-topping results mixed with upbeat guidance put Wall Street in a good mood.
Shares drop after the company announces the pricing details of a common stock offering.
Shares are tumbling after news breaks that the U.S. government has filed a lawsuit against the company.
Looking for a few bargains in today's choppy market? Consider these three healthcare gems.
Don't have time to pick your own stocks? These three funds have you covered.